Methods of treating glioblastoma multiforme using ibudilast

Abstract

Compositions and methods for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof.

1 . A method of treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma comprising administering to the patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, as part of a combination therapy comprising one or more other therapeutic agent selected from carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (Epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing. 
     
     
         2 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months. 
     
     
         3 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily. 
     
     
         4 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         5 . The method of  claim 1 , wherein the therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof is from 0.1 mg to 720 mg per day. 
     
     
         6 . The method of  claim 1 , wherein the therapeutically effective amount is administered as a single dose or is divided into two, three, or four doses. 
     
     
         7 .- 10 . (canceled) 
     
     
         11 . A method of treating a patient suffering from recurrent glioblastoma comprising administering to the patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, as part of a combination therapy comprising one or more other therapeutic agent selected from carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (Epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing. 
     
     
         12 . The method of  claim 11  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months. 
     
     
         13 . The method of  claim 11  in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily. 
     
     
         14 . The method of  claim 11  in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         15 . The method of  claim 11 , wherein the therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof is from 0.1 mg to 720 mg per day. 
     
     
         16 . The method of  claim 11 , wherein the therapeutically effective amount is administered as a single dose or is divided into two, three, or four doses. 
     
     
         17 .- 20 . (canceled)